LILLY ENDOWMENT INC, an insider at Eli Lilly and Co (LLY), sold 93,923,098 shares of the company's stock on November 4, 2025, at a price of $922.42 per share. The total transaction value amounted to $86,636.17 million.
Following this sale, LILLY ENDOWMENT INC retains an equal number of shares in Eli Lilly and Co. Insider transactions like this one are reported to the SEC, providing transparency on executives' and board members' views of their stock.
Eli Lilly & Co, headquartered in Indianapolis, Indiana, operates in the pharmaceuticals industry and employs 47,000 people. The company's diverse product portfolio includes cardiometabolic health products such as Humalog and Trulicity, oncology products like Cyramza and Verzenio, and immunology products including Olumiant and Taltz. With a market capitalization of $886.2 billion, Eli Lilly has a P/E ratio of 48.13 and an EPS of 20.45.
Investors should consider insider activity alongside other fundamental and technical factors. While this sale represents a significant transaction, it is important to view it in the context of broader insider trends rather than isolated actions. Upcoming earnings announcements include an EPS estimate of $7.70 on August 4, 2026, with expected revenue of $17.9 billion.